Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial

BACKGROUND: BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine (3 μg or 6 μg) formulated with a toll-like receptor 7/8 agonist molecule (IMDG) adsorbed to alum (Algel). We previously reported findings from a double-blind, multicentre, randomised, controlled phase 1 trial on the safety and immun...

Descripción completa

Detalles Bibliográficos
Autores principales: Ella, Raches, Reddy, Siddharth, Jogdand, Harsh, Sarangi, Vamshi, Ganneru, Brunda, Prasad, Sai, Das, Dipankar, Raju, Dugyala, Praturi, Usha, Sapkal, Gajanan, Yadav, Pragya, Reddy, Prabhakar, Verma, Savita, Singh, Chandramani, Redkar, Sagar Vivek, Gillurkar, Chandra Sekhar, Kushwaha, Jitendra Singh, Mohapatra, Satyajit, Bhate, Amit, Rai, Sanjay, Panda, Samiran, Abraham, Priya, Gupta, Nivedita, Ella, Krishna, Bhargava, Balram, Vadrevu, Krishna Mohan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8221739/
https://www.ncbi.nlm.nih.gov/pubmed/33705727
http://dx.doi.org/10.1016/S1473-3099(21)00070-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8221739/
https://www.ncbi.nlm.nih.gov/pubmed/33705727
http://dx.doi.org/10.1016/S1473-3099(21)00070-0

Ejemplares similares